Breaking
Sponsor Advertisement
FDA Declines Approval for Summit Lung Cancer Drug

FDA Declines Approval for Summit Lung Cancer Drug

The FDA declined to approve Summit's lung cancer drug, ivonescimab, after its clinical trial did not meet a key survival objective.

The U.S. Food and Drug Administration (FDA) has rejected the approval of Summit Therapeutics' lung cancer drug, ivonescimab. This decision follows a clinical trial that reportedly failed to achieve its primary survival endpoint.

The drug, which was invented in China, was closely watched within the biotech sector. Its rejection by the FDA is seen as a setback for Beijing's burgeoning biotechnology industry and delays the introduction of the PD-1xVEGF drug class in the United States.

Summit's ivonescimab was denied approval for a specific lung cancer setting. This is a developing story and will be updated as details emerge.

Advertisement

What's your view on this story? Share your thoughts and remember to consider multiple perspectives and being respectful when forming and voicing your opinion. "If you resort to personal attacks, you have already lost the debate..."

Advertisement

Contact Us About This Article

Have a question or comment about this article? We'd love to hear from you.

About Fair Side News

At Fair Side News, we believe in presenting news with perspectives from both sides of the political spectrum. Our goal is to help readers understand different viewpoints and find common ground on important issues.